|
WO2021028299A1
|
|
Viral particles for use in treating synucleinopathies such as parkinson's diseases by gene therapy
|
|
WO2021001377A1
|
|
cPLA2e INDUCING AGENTS AND USES THEREOF
|
|
WO2019243236A1
|
|
New anticancer drug combinations
|
|
WO2019057919A1
|
|
Methods and kits for the prognostic of lung adenocarcinoma
|
|
WO2019057913A1
|
|
Method and kits for the prognostic of lung squamous cell carcinoma (scc)
|
|
US2020087666A1
|
|
Compounds targeting long non coding rna for the treatment of cancer
|
|
WO2018229139A1
|
|
Novel compounds for use in cancer
|
|
WO2018162450A1
|
|
New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
|
|
AU2017349979A1
|
|
FoxP3-binding peptides and uses thereof
|
|
EP3621637A1
|
|
Human porphobilinogen deaminase derived proteins and polynucleotides and uses thereof
|
|
EP3361256A1
|
|
In vitro method for the diagnosis of lung cancer
|
|
EP3390383A1
|
|
2,4,6,7-tetrasubstituted quinoline compounds as inhibitors of dna methyltransferases
|
|
CN108431000A
|
|
New compound as dnmt rna inhibitor
|
|
BR112017012895A2
|
|
nucleic acid construct and its use, vector, host cell, viral particle, pharmaceutical composition, kit, disease treatment method, viral particle production process
|
|
EP3744351A1
|
|
Nucleic acid constructs and gene therapy vectors for use in the treatment of wilson's disease and other conditions
|
|
CA2993462A1
|
|
Products for the treatment and prevention of neurological disorders coursing with a cognition deficit or impairment, and of neurodegenerative diseases
|
|
CA2992846A1
|
|
Novel compounds for use in cognition improvement
|
|
AU2015276537A1
|
|
Novel compounds as dual inhibitors of histone methyltransferases and dna methyltransferases
|
